These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 30918432)

  • 21. Baseline serum Mac-2 binding protein glycosylation isomer as a predictor of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis.
    Witarto AP; Witarto BS; Pramudito SL; Putra AJE; Nurhadi GM; Maimunah U
    Ann Gastroenterol; 2022; 35(6):627-639. PubMed ID: 36406974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B.
    Li MR; Zheng HW; Lu JH; Ma SM; Ye LH; Liu ZQ; Zhang HC; Liu YY; Lv Y; Huang Y; Dai EH; Sun DX
    Oncotarget; 2017 Feb; 8(7):11063-11070. PubMed ID: 28052021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
    J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
    Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
    World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Performance of Mac-2-Binding Protein Glycosylation Isomer (M2BPGi), compared to Transient Elastography to Assess Liver Stiffness in Treatment Naïve Chronic Hepatitis C Patients.
    Sulaiman AS; Hasan I; Lesmana CRA; Kurniawan J; Jasirwan COM; Nababan S; Kalista KF; Hanifa RS; Rachmani D; Gani RA
    Acta Med Indones; 2022 Oct; 54(4):567-573. PubMed ID: 36624717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver fibrosis and cancer in HBV-infected patients in West Africa.
    Vincent JP; Ndow G; Ogawa S; Ceesay A; Njie R; Sanneh B; Baldeh I; D'Alessandro U; Mendy M; Thursz M; Chemin I; Tanaka Y; Lemoine M; Shimakawa Y
    J Glob Health; 2022 Nov; 12():04076. PubMed ID: 36370422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C.
    Xu H; Kong W; Liu L; Chi X; Wang X; Wu R; Gao X; Wang H; Qu L; Qi Y; Pan Y; Niu J
    BMC Gastroenterol; 2017 May; 17(1):62. PubMed ID: 28486931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs.
    Nakagawa M; Nawa N; Takeichi E; Shimizu T; Tsuchiya J; Sato A; Miyoshi M; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Fujiwara T; Watanabe M; Tanaka Y; Asahina Y;
    J Gastroenterol; 2020 Oct; 55(10):990-999. PubMed ID: 32770465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
    Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add-on therapy.
    Liu T; Sun Y; Zhou J; Yang F; Zou X; Wang L; Wu X; Chen Y; Piao H; Lu L; Jiang W; Xu Y; Feng B; Nan Y; Xie W; Chen G; Zheng H; Li H; Ding H; Liu H; Wang T; Ou X; Wu S; Kong Y; Wang P; Cong M; Zhang Y; You H; Jia J
    J Med Virol; 2019 Aug; 91(8):1499-1509. PubMed ID: 30905065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice.
    Geng M; Li Y; Gao F; Sun L; Yang X; Wang R; Chen J; Zhang Q; Wan G; Wang X
    Int J Infect Dis; 2017 Sep; 62():18-25. PubMed ID: 28669850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
    Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
    Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mac-2 binding protein glycosylation isomer at 5 years of antiviral therapy predict hepatocellular carcinoma and mortality beyond year 5 in chronic hepatitis B patients with cirrhosis.
    Chen CH; Wang JH; Lai HC; Hu TH; Hung CH; Lu SN; Peng CY
    Am J Cancer Res; 2024; 14(5):2465-2477. PubMed ID: 38859836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
    Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
    BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
    Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
    Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: A single-center retrospective study.
    Zhu YF; Tan YF; Xu X; Zheng JL; Zhang BH; Tang HR; Yang JY
    Medicine (Baltimore); 2019 Dec; 98(50):e18319. PubMed ID: 31852119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein.
    Sato S; Genda T; Ichida T; Amano N; Sato S; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Hirano K; Shimada Y; Iijima K; Wada R; Nagahara A; Watanabe S
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment.
    Zhao XA; Wang J; Liu J; Chen G; Yan X; Jia B; Yang Y; Liu Y; Gu D; Zhang Z; Xiang X; Huang R; Wu C
    Antiviral Res; 2021 Sep; 193():105146. PubMed ID: 34314774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mac-2 binding protein glycosylation isomer is a potential biomarker to predict portal hypertension and bacterial infection in cirrhotic patients.
    Wu PS; Hsieh YC; Lee KC; Huang YH; Hou MC; Lin HC
    PLoS One; 2021; 16(10):e0258589. PubMed ID: 34648567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.